ADVOS PUBLICATIONS

ADVITOS
Bridging Life

PEER-REVIEWED

Lahmer T, et al. 2026.

Extracorporeal Multiorgan Support During Prone Positioning in Severe ARDS: A Physiologic Proof-of-Concept Study

Life 2026, 16(9), 1578

PEER-REVIEWED

Triebelhorn J, et al. 2026.

Serum concentrations and pharmacokinetics of linezolid in critically ill patients dialyzed by ADVanced Organ Support compared to conventional continuous renal replacement therapy.

Eur J Clin Pharmacol. 2026 Jul 10;82(8):199. doi: 10.1007/s00228-026-04129-0.

POSTER

Himmelein S, et al. 2026.

Effizienz der Harnsäure-Elimination mittels ADVOS im in vitro Tumorlysesyndrom-Modell. Abstracts der 57. Gemeinsamen Jahrestagung der ÖGIAIN und DGIIN.

Med Klin Intensivmed Notfmed 121, 417–444 (2026). https://doi.org/10.1007/s00063-026-01447-0.

PEER-REVIEWED

Fuhrmann V, et al. 2025.

The Advanced Organ Support (ADVOS) hemodialysis system fulfills its intended purpose: Analysis of data from 282 patients from the Registry on Extracorporeal Multiple Organ Support (EMOS).

PLoS One. 2025 Dec 4;20(12):e0318917. doi: 10.1371/journal.pone.0318917. eCollection 2025.

PEER-REVIEWED

Dibos M, et al. 2025.

The ADVanced Organ Support (ADVOS) hemodialysis system balances blood pH within24 h in patients with multiple organ failure and hypercapnic acidosis.

Intensive Care Med Exp. 2025 Oct 25;13(1):108. doi: 10.1186/s40635-025-00820-1

PEER-REVIEWED

Panholzer B, et al. 2025.

Accelerated Apixaban Removal by Using the ADVanced Organ Support (ADVOS) Albumin Hemodialysis System-A Case Report.

Thorac Cardiovasc Surg Rep. 2025 Sep 15;14(1):e24-e28. doi: 10.1055/a-2682-8640

PEER-REVIEWED

Schönfelder K, et al. 2025.

Artificial liver support with Cytosorb and continuous veno-venous hemodiafiltration versus advanced organ support (ADVOS) for critically ill patients with hyperbilirubinemia and acute-on-chronic liver failure

ACLF). BMC Nephrol. 2025 Aug 4;26(1):432. doi: 10.1186/s12882-025-04342-6

PEER-REVIEWED

Walter V, et al. 2025.

The ADVanced Organ Support (ADVOS) Hemodialysis System in Postoperative Cardiogenic Shock and Multiple Organ Failure: First Results in Cardiac Surgery Patients.

Life 2025, 15(7), 1042 https://doi.org/10.3390/life15071042

PEER-REVIEWED

Totschnig D, et al. 2025.

Meropenem plasma concentrations in critically ill patients treated with the novel multi organ replacement therapy ADVOS.

Infection (2025). https://doi.org/10.1007/s15010-025-02554-4

ABSTRACT

Himmelein S, et al. 2025.

The advanced organ support (ADVOS) hemodialysis system can remove myoglobin from blood: a proof-of-concept in vitro study.

Critical Care 2025, 29(S1):P062

ABSTRACT

Triebelhorn J, et al. 2025.

Comparison of linezolid elimination in albumin-based ADVOS dialysis versus conventional CVVHD in critically ill patients.

Critical Care 2025, 29(S1):P278

PEER-REVIEWED

König C, et al. 2024.

In vitro elimination of antimicrobials during ADVanced Organ Support hemodialysis.

Front. Pharmacol. 15:1447511. doi: 10.3389/fphar.2024.1447511

PEER-REVIEWED

Himmelein S, et al. 2024.

The ADVanced Organ Support (ADVOS) hemodialysis system removes IL-6: an in vitro proof-of- concept study.

Intensive Care Med Exp. 2024 Jul 31;12(1):66 doi: 10.1186/s40635-024-00652-5

ABSTRACT

Lahmer T, et al. 2024.

The advanced organ support (ADVOS) hemodialysis system balances blood pH within 24 h in patients with multiple organ failure and hypercapnic acidosis.

Critical Care 2024, 28(Suppl 1):68 https://doi.org/10.1186/s13054-024-04822-5

ABSTRACT

Weinmann-Menke J, et al. 2024.

Advanced organ support (ADVOS) in patients with acute-on-chronic liver failure: subgroup analysis of the Registry on Extracorporeal Multiple Organ Support.

Intensive Care Medicine Experimental 2023, 11(Suppl 1):72

ABSTRACT

Jahn M, et al. 2023.

Extracorporeal liver support in acute-on-chronic liver failure grade 3 – ADVanced Organ Support versus plasma exchange.

Intensive Care Medicine Experimental 2023, 11(Suppl 1)

PEER-REVIEWED

Sommerfeld O, et al. 2023.

Extracorporeal albumin dialysis in critically ill patients with liver failure: Comparison of four different devices—A retrospective analysis.

Intensive Care MedInt J Artif Organs. 2023 Sep;46(8-9):481-491. doi: 10.1177/03913988231191952. icine Experimental 2023, 11(Suppl 1):72

ABSTRACT

Fuhrmann V, et al. 2023.

Significant reduction of the standardized mortality ratio in patients with multiple organ failure treated withtheAdvanced organ support (ADVOS): analysis of the Registry on Extracorporeal Multiple Organ Support for patients with documented SOFA scores.

Critical Care 2023, 27(S1): P310

PEER-REVIEWED

Acharya MP, et al. 2022.

The role of the ADVanced Organ Support (ADVOS) system in critically ill patients with multiple organ failure.

Artif Organs. 2022 Feb 06. doi: 10.1111/aor.14188

PEER-REVIEWED

Kaps L, et al. 2022.

Influence of Advanced Organ Support (ADVOS) on Cytokine Levels in Patients with Acute-on-Chronic Liver Failure (ACLF).

J. Clin. Med. 2022, 11(10), 2782; doi: 10.3390/jcm11102782

ABSTRACT

Frey O, et al. 2022.

In vitro Bestimmung der Antibiotika-Clearance mit dem ADVanced Organ Support (ADVOS) Hämodialysesystem.

DIVI 2022 – Abstractbuch - EP/ 12 /03

ABSTRACT

Perez A, et al. 2022.

Effektive Entfernung von IL-6 mit dem ADVanced Organ Support (ADVOS)-Verfahren: Proof-of- Concept in vitro.

DIVI 2022 – Abstractbuch - EP/ 12 /02

ABSTRACT

Fuhrmann V, et al. 2022.

Advanced organ support (ADVOS) in patients with acidosis and multiple organ failure: subgroup analysis of the registry on extracorporeal multiple organ support.

Critical Care 2022, 26(Suppl 1): P143

PEER-REVIEWED

Fuhrmann V, et al. 2021.

Registry on extracorporeal multiple organ support with the advanced organ support (ADVOS) system: 2-year interim analysis.

Medicine (Baltimore). 2021 Feb 19;100(7):e24653

PEER-REVIEWED

Allescher J, et al. 2021.

Extracorporeal carbon dioxide Removal (ECCO2R) with the Advanced Organ Support (ADVOS) system in critically ill COVID-19 patients.

Artif Organs.2021 Jul 26. doi: 10.1111/aor.14044

PEER-REVIEWED

Fuhrmann V,etal. 2020.

Advanced organ support (ADVOS) in the critically ill: first clinical experience in patients with multiple organ failure.

Annals of Intensive Care volume 10, Article number: 96 (2020)